Defence Therapeutics (TSE:DTC) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Defence Therapeutics, a Canadian biopharmaceutical firm, has announced the offering of new unsecured convertible debentures aimed at raising up to CAD$1,570,000. These debentures, offering an 8% interest rate, are convertible into common shares, potentially resulting in the issuance of over 2.6 million shares. This financial move is part of the company’s strategy to settle outstanding debt while continuing to advance its innovative biopharmaceutical technologies.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money